MedTrace Logo

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

NCT05921448 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-25

No results posted yet for this study

Summary

The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

Vaxigripetra

Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.

BIOLOGICAL

Flumist

Tetravalent live attenuated influenza vaccine administered as a nasal spray. Mechanism of action: Not fully understood according to the prescribing information, but may involve influenza-specific T-cells and antibodies (serum and mucosal).

Sponsors & Collaborators

  • The Novo Nordic Foundation

    collaborator OTHER

  • Copenhagen Respiratory Research

    lead NETWORK

Principal Investigators

  • Jens-Ulrik Stæhr Jensen, MD, PhD · Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-19
Primary Completion
2026-07-27
Completion
2026-07-27

Countries

  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05921448 on ClinicalTrials.gov